1. Home
  2. BETR vs FULC Comparison

BETR vs FULC Comparison

Compare BETR & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Better Home & Finance Holding Company

BETR

Better Home & Finance Holding Company

N/A

Current Price

$13.06

Market Cap

275.0M

Sector

Finance

ML Signal

N/A

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

N/A

Current Price

$3.81

Market Cap

285.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BETR
FULC
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.0M
285.4M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
BETR
FULC
Price
$13.06
$3.81
Analyst Decision
Buy
Buy
Analyst Count
1
8
Target Price
$40.00
$16.38
AVG Volume (30 Days)
659.9K
1.6M
Earning Date
05-07-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
20.88
N/A
EPS
N/A
N/A
Revenue
$164,872,000.00
N/A
Revenue This Year
$55.02
N/A
Revenue Next Year
$65.66
N/A
P/E Ratio
N/A
N/A
Revenue Growth
51.97
N/A
52 Week Low
$11.11
$2.83
52 Week High
$94.06
$15.74

Technical Indicators

Market Signals
Indicator
BETR
FULC
Relative Strength Index (RSI) 41.99 47.58
Support Level $11.55 $3.44
Resistance Level $15.30 $3.92
Average True Range (ATR) 1.28 0.07
MACD 0.45 -0.00
Stochastic Oscillator 50.17 18.52

Price Performance

Historical Comparison
BETR
FULC

About BETR Better Home & Finance Holding Company

Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: